Objectives. To evaluate the effects of atomoxetine on complex attention and other neurocognitive domains in idiopathic Parkinson’s disease (PD). Methods. Interventional trials reporting changes in complex attention and other neurocognitive functions (Diagnostic and Statistical Manual of Mental Disorders-5) following administration of atomoxetine for at least 8 weeks in adults with idiopathic PD were included. Effect sizes (Cohen’s d), the standardized mean difference in the scores of each cognitive domain, were compared using a random-effects model (MetaXL version 5.3). Results. Three studies were included in the final analysis. For a change in complex attention in PD with mild cognitive impairment (MCI), the estimated effect size was small and nonsignificant (0.16 (95% CI: −0.09, 0.42), n = 42). For changes in executive function, perceptual-motor function, language, social cognition, and learning and memory, the estimated effect sizes were small and medium, but nonsignificant. A deteriorative trend in executive function was observed after atomoxetine treatment in PD with MCI. For a change in global cognitive function in PD without MCI, the estimated effect size was large and significant. Conclusion. In idiopathic PD with MCI, atomoxetine does not improve complex attention. Also, a deteriorative trend in the executive function was noted.

中文翻译：

---

托莫西汀不能改善有认知缺陷的特发性帕金森病患者的复杂注意力：荟萃分析

目标。评估托莫西汀对特发性帕金森病 (PD) 复杂注意力和其他神经认知领域的影响。方法。纳入报告在患有特发性 PD 的成人中服用托莫西汀至少 8 周后复杂注意力和其他神经认知功能（精神疾病诊断和统计手册 5）发生变化的干预性试验。使用随机效应模型（MetaXL 5.3 版）比较效应量（Cohen's d），即每个认知领域得分的标准化平均差。结果. 三项研究纳入最终分析。对于伴有轻度认知障碍 (MCI) 的 PD 复杂注意力的变化，估计的效应量很小且不显着（0.16（95% CI：-0.09, 0.42），n  = 42）。对于执行功能、感知运动功能、语言、社会认知以及学习和记忆的变化，估计的影响大小为中小，但不显着。在用 MCI 治疗 PD 后，观察到执行功能的恶化趋势。对于没有 MCI 的 PD 中全局认知功能的变化，估计的效应量很大且显着。结论。在患有 MCI 的特发性 PD 中，托莫西汀不会改善复杂的注意力。此外，还注意到执行功能的恶化趋势。